POC study of a new radioimmunotherapy targeting molecules response to therapy

2019 Fiscal Year Final Research Report

• Project/Area Number: 17K10497
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Radiation science
• Research Institution: National Institutes for Quantum and Radiological Science and Technology
• Principal Investigator: Sugyo Aya 国立研究開発法人量子科学技術研究開発機構, 放射線医学総合研究所 分子イメージング診断治療研究部, 主任技術員(任常) (00415415)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Keywords: 膵がんモデルマウス / RIT / CD147

Outline of Final Research Achievements

We selected CD147 as a target molecule response to therapy. The efficacy of combined treatment of X-rays radiation therapy and gemcitabine (Gem) in a pancreatic cancer model was more effective than Gem or X-ray monotherapy. Cell binding assays showed that 111In-labeled CD147 antibody bound to pancreatic cancer cells. Biodistribution of 111In-labeled antibody in tumor-bearing mice. The radiolabeled antibody bound highly to cells and accumulated highly in pancreatic cancer xenografted tumors but low in major normal organs. To evaluate the therapeutic efficacy, tumor volumes and body weights were periodically measured in mice receiving Gem, radioimmunotherapy (RIT), and both RIT and Gem. Combined treatment using RIT with Gem significantly suppressed tumor growth and the efficacy was superior than the other treatments.

Free Research Field

分子イメージング

Academic Significance and Societal Importance of the Research Achievements

効果的な転移がんの治療法の開発が社会から強く求められており、転移がんの治療として、主に化学療法が行われているが、現状では治療効果は低いことが大きな問題である。放射線療法は、全身性の治療に適していないが、標的アイソトープ治療(Targeted Radioisotope Therapy, TRT)は、化学療法と同様に全身性の治療であり、転移がんの治療に利用できる。放射線増感効果のある抗がん剤等により発現誘導される分子(治療応答分子)を標的とした放射免疫療法(Radioimmunotherapy, RIT)により、増感効果と総吸収線量の増加を両立させることで、治療効果の向上を図るものである。